Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Is cibinqo an oral treatment for eczema?

See the DrugPatentWatch profile for cibinqo

Yes, Cibinqo Is an Oral Treatment for Eczema


Cibinqo (abrocitinib) is an FDA-approved oral tablet taken once daily for moderate-to-severe atopic dermatitis, commonly known as eczema, in adults whose skin doesn't fully clear with topical therapies.[1]

How Does Cibinqo Work for Eczema?

It selectively inhibits Janus kinase 1 (JAK1), a protein that drives inflammation in eczema. This reduces itching, redness, and skin lesions, with clinical trials showing 40-60% of patients achieving clear or almost clear skin after 12 weeks at 100mg or 200mg doses.[1][2]

Who Can Use It and When?

Approved for patients 12+ years old (recently expanded) who have tried topical treatments without success. It's not first-line; doctors start with creams or light therapy. A black box warning covers serious infections, blood clots, heart issues, and cancer risk due to JAK inhibitor class effects.[1]

Common Side Effects Patients Report

Nausea (up to 18%), headache (14%), acne (11%), and herpes infections. Long-term use raises cholesterol and infection risks; regular blood tests are required.[1][2]

How Does It Compare to Dupixent or Other Eczema Drugs?

Unlike injectable Dupixent (dupilumab), which targets IL-4/IL-13, Cibinqo is a convenient pill but carries higher systemic risks. It clears skin faster than methotrexate but similar to Rinvoq (upadacitinib, another JAK inhibitor). Cost: ~$5,000/month without insurance.[2][3]

Patent Status and Availability

Pfizer holds U.S. patents on Cibinqo until around 2032-2037, depending on formulation; no generics yet. Check DrugPatentWatch.com for challenges or expirations.[4]

[1]: FDA Label - Cibinqo (abrocitinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213871s000lbl.pdf
[2]: JAAD - Abrocitinib Phase 3 Trials. https://www.jaad.org/article/S0190-9622(20)32148-4/fulltext
[3]: NEJM - JAK Inhibitors in Atopic Dermatitis. https://www.nejm.org/doi/full/10.1056/NEJMoa2107683
[4]: DrugPatentWatch.com - Abrocitinib Patents. https://www.drugpatentwatch.com/p/tradename/CIBINQO



Other Questions About Cibinqo :

Is Cibinqo an oral treatment for eczema? Is cibinqo an oral treatment for eczema?




DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy